K76.0 E66.0
Conditions
Interventions
Group 1: Comparison of serum FGF19 concentrations between overweight and obese NAFLD patients and healthy subjects (fasted and after oral fat load)
Group 1: overweight NAFLD subjects
Group 2: Compar
Sponsors
Universität des Saarlandes
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: written consent, Age: >18 years, Controls: healthy and normal weight (BMI 19.0-25.4 kg / m²), overweight subjects (BMI 25.5-29.9 kg/m²) + NAFLD, obese subjects (BMI = 30 kg m²) + NAFLD, Liver diagnostics in overweight and obese by ultrasound and/or liver biopsy
Exclusion criteria
Exclusion criteria: missing declaration of consent, NAFLD patients: increased alcohol consumption in medical history and the following acute and chronic liver diseases: cirrhosis, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) infections, hemochromatosis, Wilson's disease, a1-antitrypsin deficiency, and autoimmune hepatitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting FGF19 serum concentration and 2, 4 and 6 hours after body-weight-adjusted oral fat load | — |
Secondary
| Measure | Time frame |
|---|---|
| Concentrations of bile acids and bile acid synthesis marker 7a-hydroxy-4-cholesten-3-one (C4) are measured by gas chromatography-mass spectrometry and high-performance liquid chromatography, respectively; all at 0 (baseline), 2, 4 and 6 hours during the OFTT. | — |
Countries
Germany
Contacts
Public ContactFrank Lammert
Universitätsklinikum des SaarlandesKlinik für Innere Medizin II
Outcome results
None listed